Headlines about BIOLINERX Ltd/S (NASDAQ:BLRX) have been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BIOLINERX Ltd/S earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.7392940703494 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities analysts recently commented on BLRX shares. Zacks Investment Research upgraded BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research report on Thursday, August 16th. HC Wainwright set a $4.00 target price on BIOLINERX Ltd/S and gave the stock a “buy” rating in a research report on Tuesday, August 14th. Maxim Group restated a “buy” rating and set a $2.00 target price on shares of BIOLINERX Ltd/S in a research report on Monday, August 13th. ValuEngine upgraded BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Finally, MED started coverage on BIOLINERX Ltd/S in a research report on Wednesday, August 1st. They set a “market perform” rating for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $2.50.
Shares of BLRX remained flat at $$0.93 during midday trading on Thursday. The stock had a trading volume of 332,090 shares, compared to its average volume of 328,901. BIOLINERX Ltd/S has a 1 year low of $0.78 and a 1 year high of $1.34. The stock has a market cap of $99.04 million, a PE ratio of -3.46 and a beta of 0.58.
BIOLINERX Ltd/S (NASDAQ:BLRX) last posted its quarterly earnings data on Monday, August 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. equities analysts anticipate that BIOLINERX Ltd/S will post -0.22 earnings per share for the current fiscal year.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Further Reading: NASDAQ
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.